|
Anavex Life Sciences Corp (NASDAQ: AVXL) |
|
Anavex Life Sciences Corp
AVXL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Anavex Life Sciences 's sales fell
in I. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1168
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.45 %
Anavex Life Sciences net loss increased from $-9 millions, to $-12 millions in I. Quarter 2024,
• More on AVXL's Growth
|
|
Anavex Life Sciences realized a net loss in trailing twelve months.
Anavex Life Sciences realized cash reduction of $ -0.27 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 450.32.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.14.
• More on AVXL's Valuation
|
|
|
|
|
Anavex Life Sciences realized net loss in trailing twelve months.
Anavex Life Sciences realized cash outflow of $ -0.27per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 450.32.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.14.
Anavex Life Sciences Price to Book Ratio is at 7.2 lower than Industry Avg. of 18124.01. and higher than S&P 500 Avg. of 0.01
• More on AVXL's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com